<code id='56D3DED49C'></code><style id='56D3DED49C'></style>
    • <acronym id='56D3DED49C'></acronym>
      <center id='56D3DED49C'><center id='56D3DED49C'><tfoot id='56D3DED49C'></tfoot></center><abbr id='56D3DED49C'><dir id='56D3DED49C'><tfoot id='56D3DED49C'></tfoot><noframes id='56D3DED49C'>

    • <optgroup id='56D3DED49C'><strike id='56D3DED49C'><sup id='56D3DED49C'></sup></strike><code id='56D3DED49C'></code></optgroup>
        1. <b id='56D3DED49C'><label id='56D3DED49C'><select id='56D3DED49C'><dt id='56D3DED49C'><span id='56D3DED49C'></span></dt></select></label></b><u id='56D3DED49C'></u>
          <i id='56D3DED49C'><strike id='56D3DED49C'><tt id='56D3DED49C'><pre id='56D3DED49C'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:45363
          Influenza A virions
          F. A. Murphy/CDC

          Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

          Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

          advertisement

          The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          GOP hopefuls to address prominent, controversial group questioning what's taught in schools
          GOP hopefuls to address prominent, controversial group questioning what's taught in schools

          1:29AmemberofMomsforLibertyprotestsagainstmandatoryfacemasksforstudentsduringtheCOVID-19pandemicatam

          read more
          New air purifier tech could be key to improving indoor air quality
          New air purifier tech could be key to improving indoor air quality

          AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

          read more

          What the cancer research community can learn from the Covid response

          TinaReed,PaulKluetz,JohnOyler,andSolangePetersspeakattheMilkenInstituteFutureofHealthSummit.Screenca